CoChat
Sign Up
Cited by 30

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift

LaDu, Mary Jo, Munson, Gregory W., Jungbauer, Lisa, Getz, Godfrey S., Reardon, Catherine A., Tai, Leon M., Yu, Chunjiang·2012·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
DOI 10.1016/j.bbalip.2011.11.005PMC PMC3273043
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbalip.2011.11.005

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Aβ has also been reported to associate with ApoE specifically, in contrast to ApoJ containing lipoprotein for instance, in human CSF.

    “Aβ has also been reported to associate with ApoE specifically, in contrast to ApoJ containing lipoprotein for instance, in human CSF [83, 84].”

    From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [84]

    Results §3.2 reports that endogenous Aβ in the human CSF sample was associated with apoE-containing lipoproteins, and identifies a portion in an apoE/Aβ complex. The paper does not report a comparison with ApoJ-containing lipoproteins, so the claimed contrast is unsupported. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 54

  1. Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, 261, 921, 10.1126/science.8346443 · DOI · Paper page
  2. Elliott, 2010, Apolipoproteins in the brain: implications for neurological and psychiatric disorders, J. Clin. Lipidol., 51, 555, 10.2217/clp.10.37 · DOI · Paper page
  3. Xu, 2006, Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus, J. Neurosci., 26, 4985, 10.1523/JNEUROSCI.5476-05.2006 · DOI · Paper page
  4. Yu, 2010, Proposed mechanism for lipoprotein remodelling in the brain, Biochim. Biophys. Acta, 1801, 819, 10.1016/j.bbalip.2010.05.001 · DOI
  5. Hauser, 2011, Apolipoprotein E: from lipid transport to neurobiology, Prog. Lipid Res., 50, 62, 10.1016/j.plipres.2010.09.001 · DOI · Paper page
  6. Koudinov, 1994, The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma, Biochem. Biophys. Res. Commun., 205, 1164, 10.1006/bbrc.1994.2788 · DOI
  7. Biere, 1996, Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma, J. Biol. Chem., 271, 32916, 10.1074/jbc.271.51.32916 · DOI · Paper page
  8. Scharnagl, 1999, The betaA4 amyloid peptide complexes to and enhances the uptake of beta-very low density lipoproteins by the low density lipoprotein receptor-related protein and heparan sulfate proteoglycans pathway, Lab. Invest., 79, 1271
  9. Koudinov, 1998, Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids, Clin. Chim. Acta, 270, 75, 10.1016/S0009-8981(97)00207-6 · DOI
  10. Permanne, 1997, Detection of apolipoprotein E/dimeric soluble amyloid ß complexes in Alzheimer's disease brain supernatants, Biochem. Biophys. Res. Commun., 240, 715, 10.1006/bbrc.1997.7727 · DOI · Paper page
  11. Koudinov, 2001, The levels of soluble amyloid beta in different high density lipoprotein subfractions distinguish Alzheimer's and normal aging cerebrospinal fluid: implication for brain cholesterol pathology?, Neurosci. Lett., 314, 115, 10.1016/S0304-3940(01)02263-7 · DOI
  12. Koudinov, 1996, Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins, Biochem. Biophys. Res. Commun., 223, 592, 10.1006/bbrc.1996.0940 · DOI
  13. Fagan, 2000, Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype, Ann. Neurol., 48, 201, 10.1002/1531-8249(200008)48:2<201::AID-ANA10>3.0.CO;2-X · DOI
  14. Sagare, 2007, Clearance of amyloid-beta by circulating lipoprotein receptors, Nat. Med., 13, 1029, 10.1038/nm1635 · DOI · Paper page
  15. Matsubara, 2004, Soluble Abeta homeostasis in AD and DS: impairment of anti-amyloidogenic protection by lipoproteins, Neurobiol. Aging, 25, 833, 10.1016/j.neurobiolaging.2003.10.004 · DOI
  16. Mamo, 2008, Plasma lipoprotein beta-amyloid in subjects with Alzheimer's disease or mild cognitive impairment, Ann. Clin. Biochem., 45, 395, 10.1258/acb.2008.007214 · DOI
  17. Koudinov, 1999, HDL phospholipid: a natural inhibitor of Alzheimer's amyloid beta-fibrillogenesis?, Clin. Chem. Lab. Med., 37, 993, 10.1515/CCLM.1999.148 · DOI
  18. Cole, 1999, Lipoprotein effects on Abeta accumulation and degradation by microglia in vitro, J. Neurosci. Res., 57, 504, 10.1002/(SICI)1097-4547(19990815)57:4<504::AID-JNR10>3.0.CO;2-H · DOI
  19. LaDu, 1995, Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid, J. Biol. Chem., 270, 9039, 10.1074/jbc.270.16.9039 · DOI · Paper page
  20. LaDu, 1997, Association of human, rat, and rabbit apolipoprotein E with beta-amyloid, J. Neurosci. Res., 49, 9, 10.1002/(SICI)1097-4547(19970701)49:1<9::AID-JNR2>3.0.CO;2-H · DOI
  21. Bentley, 2002, Apolipoprotein E structural requirements for the formation of SDS-stable complexes with beta-amyloid-(1–40): the role of salt bridges, Biochem. J., 366, 273, 10.1042/bj20020207 · DOI
  22. Morikawa, 2005, Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta, Neurobiol. Dis., 19, 66, 10.1016/j.nbd.2004.11.005 · DOI · Paper page
  23. Strittmatter, 1993, Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease, Proc. Natl. Acad. Sci. U.S.A., 90, 1977, 10.1073/pnas.90.5.1977 · DOI · Paper page
  24. Russo, 1998, Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease, Proc. Natl. Acad. Sci. U.S.A., 95, 15598, 10.1073/pnas.95.26.15598 · DOI
  25. Golabek, 1996, The interaction between apolipoprotein E and Alzheimer's amyloid ß-peptide is dependent on ß-peptide conformation, J. Biol. Chem., 271, 10602, 10.1074/jbc.271.18.10602 · DOI
  26. Pillot, 1997, Specific modulation of the fusogenic properties of the Alzheimer beta-amyloid peptide by apolipoprotein E isoforms, Eur. J. Biochem., 243, 650, 10.1111/j.1432-1033.1997.00650.x · DOI
  27. Pillot, 1999, Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease, J. Neurochem., 72, 230, 10.1046/j.1471-4159.1999.0720230.x · DOI
  28. Yamauchi, 2000, Effect of apolipoprotein AII on the interaction of apolipoprotein E with beta-amyloid: some apo(E-AII) complexes inhibit the internalization of beta-amyloid in cultures of neuroblastoma cells, J. Neurosci. Res., 62, 608, 10.1002/1097-4547(20001115)62:4<608::AID-JNR16>3.0.CO;2-4 · DOI
  29. Koch, 2001, Characterization of four lipoprotein classes in human cerebrospinal fluid, J. Lipid Res., 42, 1143, 10.1016/S0022-2275(20)31605-9 · DOI · Paper page
  30. Castro, 1984, Evidence for the distribution of apolipoprotein E between lipoprotein classes in human normocholesterolemic plasma and for the origin of unassociated apolipoprotein E (Lp-E), J. Lipid Res., 25, 58, 10.1016/S0022-2275(20)37844-5 · DOI
  31. Corbo, 1999, Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele?, Ann. Hum. Genet., 63, 301, 10.1046/j.1469-1809.1999.6340301.x · DOI
  32. Folin, 2004, Apolipoprotein E as vascular risk factor in neurodegenerative dementia, Int. J. Mol. Med., 14, 609
  33. Mooijaart, 2007, Plasma levels of apolipoprotein E and cognitive function in old age, Ann. N. Y. Acad. Sci., 1100, 148, 10.1196/annals.1395.013 · DOI
  34. Panza, 2003, Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians, Neuroreport, 14, 605, 10.1097/00001756-200303240-00016 · DOI
  35. Siest, 2000, Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group, Clin. Chem. Lab. Med., 38, 721, 10.1515/CCLM.2000.102 · DOI
  36. Slooter, 1997, Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation, JAMA, 277, 818, 10.1001/jama.1997.03540340052032 · DOI
  37. van Vliet, 2007, Plasma levels of apolipoprotein E and risk of stroke in old age, Ann. N. Y. Acad. Sci., 1100, 140, 10.1196/annals.1395.012 · DOI
  38. van Vliet, 2009, APOE genotype modulates the effect of serum calcium levels on cognitive function in old age, Neurology, 72, 821, 10.1212/01.wnl.0000343852.10018.24 · DOI
  39. Lichtlen, 2008, Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools, J. Neurochem., 104, 859, 10.1111/j.1471-4159.2007.05064.x · DOI
  40. Yaffe, 2011, Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline, JAMA, 305, 261, 10.1001/jama.2010.1995 · DOI
  41. Carlsson, 1991, Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid, Clin. Chim. Acta, 196, 167, 10.1016/0009-8981(91)90070-S · DOI
  42. Hesse, 2000, Measurement of apolipoprotein E (apoE) in cerebrospinal fluid, Neurochem. Res., 25, 511, 10.1023/A:1007516210548 · DOI
  43. Wahrle, 2007, Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms, Mol. Neurodegener., 2, 7, 10.1186/1750-1326-2-7 · DOI · Paper page
  44. LaDu, 2006, Self-assembly of HEK cell-secreted ApoE particles resembles ApoE enrichment of lipoproteins as a ligand for the LDL receptor-related protein, Biochemistry, 45, 381, 10.1021/bi051765s · DOI · Paper page
  45. Manelli, 2004, ApoE and Abeta1–42 interactions: effects of isoform and conformation on structure and function, J. Mol. Neurosci., 23, 235, 10.1385/JMN:23:3:235 · DOI · Paper page
  46. Ladu, 2000, Lipoproteins in the central nervous system, Ann. N. Y. Acad. Sci., 903, 167, 10.1111/j.1749-6632.2000.tb06365.x · DOI · Paper page
  47. Sun, 1998, Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins, J. Neurosci., 18, 3261, 10.1523/JNEUROSCI.18-09-03261.1998 · DOI · Paper page
  48. Lui, 2010, Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging, J. Alzheimers Dis., 20, 1233, 10.3233/JAD-2010-090249 · DOI
  49. Graff-Radford, 2007, Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease, Arch. Neurol., 64, 354, 10.1001/archneur.64.3.354 · DOI
  50. Yanagisawa, 1995, GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease, Nat. Med., 1, 1062, 10.1038/nm1095-1062 · DOI
  51. McLaurin, 1996, Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity, J. Biol. Chem., 271, 26482, 10.1074/jbc.271.43.26482 · DOI
  52. Hayashi, 2004, A seed for Alzheimer amyloid in the brain, J. Neurosci., 24, 4894, 10.1523/JNEUROSCI.0861-04.2004 · DOI
  53. Waschuk, 2001, Cellular membrane composition defines A beta-lipid interactions, J. Biol. Chem., 276, 33561, 10.1074/jbc.M103598200 · DOI
  54. Cai, 2004, Serum amyloid A is a ligand for scavenger receptor SR-BI and inhibits HDL binding and selective lipid uptake, J. Biol. Chem., 280, 2954, 10.1074/jbc.M411555200 · DOI

Cited by

Sorted by citations

Metadata

Authors
LaDu, M. J., Munson, G. W., Jungbauer, L., Getz, G. S., Reardon, C. A., Tai, L. M., & Yu, C.
Venue
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Publisher
Elsevier BV
Published
2012-02
Volume
1821
Issue
2
Pages
295-302
ISSN
1388-1981
DOI
10.1016/j.bbalip.2011.11.005
PMC
PMC3273043
Cited by
30
References
12
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review